Fig. 2From: MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancerMC180295 and its enantiomers, MC180379 and MC180380, ability to epigenetically reactivate GFP expression in the YB5 reporter system. A Structures of MC180295 and its enantiomers, MC180379 and MC180380. Expression of GFP (measured by FACS), B 24 h, and C 4 days, after a one-time treatment of YB5 cells with MC180379, MC180380, MC180295, and a one-to-one mixture of MC180379 and MC180380. Data are shown as means ± SDs, n = 3. *p < 0.05, ***p < 0.001Back to article page